Antengene Corporation Limited (FRA:722)

Market Cap	225.86M -40.7%
Revenue (ttm)	72.83M +570.1%
Net Income	6.91M
EPS	0.01
Shares Out	n/a
PE Ratio	27.89
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	300
Open	0.3080
Previous Close	0.3060
Day's Range	0.3080 - 0.3080
52-Week Range	0.2860 - 0.6450
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 20, 2026

About Antengene Corporation

Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company’s commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor f...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 122
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 722

Financial Performance

In 2025, Antengene Corporation's revenue was 105.34 million, an increase of 14.56% compared to the previous year's 91.95 million. Losses were -239.13 million, -25.10% less than in 2024.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error